Alexion shares sink after Soliris fails Phase II testing; Eli Lilly names new senior VP to corporate business development unit;

@FiercePharma: ICYMI yesterday: New study clears Merck's blockbuster Gardasil of MS risk. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Valneva picks up J&J's cholera vaccine--and some forthcoming competition. More | Follow @CarlyHFierce

> Alexion Pharmaceuticals ($ALXN) said its Soliris blood-clotting treatment did not meet its goals in a Phase II clinical trial, sending the company's shares into a downward spiral. More

> Eli Lilly ($LLY) promoted Darren Carroll to senior vice president of its corporate business development unit. Story

> A Delaware judge ordered Siga Technologies to pay PharmAthene $113.1 million in damages in a licensing dispute over Siga's antiviral smallpox drug Tecovirimat. More

> Horizon Pharma rounded out 2014 with an estimated $290 million in revenue thanks to standout performances of pain pills Duexis and Vimovo, and analysts are forecasting more sales success in the coming year. Story

> GW Pharmaceuticals ($GWPH) and Otsuka Pharmaceutical revealed that their cannabis-based drug Sativex did not show any statistically significant difference than a placebo in the first of three Phase III trials. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Alere snags first FDA CLIA waiver for molecular influenza test. Article | Follow @FierceMedDev

@EmilyWFierce: Hedge fund exec aims new legal weapon at Big Pharma's 'evergreened' patents. Story | Follow @EmilyWFierce

> 23andMe's $60M deal with Genentech shows an alternative path forward for diagnostics companies. News

> FDA lifts import restriction on Hospira as it aims to reinvigorate its infusion pumps. Article

Biotech News

@FierceBiotech: Biogen Idec's remyelination drug raises hopes--and some fears--in Phase II. Story | Follow @FierceBiotech

@JohnCFierce: Anybody who says that statistical significance is not expected in a study is playing defense for a stock. | Follow @JohnCFierce

@DamianFierce: No FDA panel scheduled for Pizer's palbociclib, which $PFE hopes to get approved as Ibrance before April deadline. More | Follow @DamianFierce

> Novartis clears an FDA hurdle with its pioneering biosimilar of Amgen's Neupogen. News

> Atlas seedling banks $35M to feel out the future of immuno-oncology. Story

Vaccines News

> Pfizer's growth spurt continues with pickup of Switzerland's Redvax. Report

> Swiss trial of Merck/NewLink Ebola vaccine resumes at lower dose. Article

> Valneva picks up J&J's cholera vaccine--and some forthcoming competition. Story

> No link between Merck's Gardasil and MS risk, study shows. Item

> Johnson & Johnson is third to bring Ebola vaccine to trials, but is it too late? More

Pharma Manufacturing News

> Impax Labs overcomes manufacturing issues to get Parkinson's drug approved. More

> Arena, Eisai have to recall nearly 122,000 bottles of Belviq over labeling glitch. Article

> France and Italy ban products from Indian companies. More

> Drugmakers ask Supreme Court to squelch California drug takeback law. Story

> China regulator promises action to fix 'grim' drug safety situation. Article

And Finally… A new study found that monthly injections of testosterone could shrink tumors in patients with prostate cancer, delivering a surprise to researchers. Story